Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 9:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Renin-angiotensin System Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Renin Angiotensin Aldosterone System In Septic Kids

NCT06295393
View directory record Official record
Conditions
Sepsis, Acute Kidney Injury Due to Sepsis, Acute Kidney Injury (Nontraumatic)
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
1 Day to 18 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jul 24, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors

NCT00421733
View directory record Official record
Conditions
Diabetic Nephropathy, Chronic Kidney Disease
Interventions
Zemplar (paricalcitol) capsules, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
27
States / cities
Phoenix, Arizona • Fountain Valley, California • Yuba City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Jul 24, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

NCT03217591
View directory record Official record
Conditions
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Interventions
IW-1973, Placebo
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
25 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
54
States / cities
Birmingham, Alabama • Chula Vista, California • Fullerton, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Jul 24, 2026, 9:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury

NCT06282965
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Angiotensin (1-7), Sterile saline
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 24, 2026, 9:14 AM EDT
Completed Phase 4 Interventional Results available

To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study

NCT02299388
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease
Interventions
Liraglutide or Placebo
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Jul 24, 2026, 9:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3

NCT00685945
View directory record Official record
Conditions
Obesity
Interventions
Control (bradykinin), L-NMMA + bradykinin, Isosorbide + L-NMMA + bradykinin, Sildenafil + L-NMMA + bradykinin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Jul 24, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function

NCT01320722
View directory record Official record
Conditions
Renal Function, Endothelial Function, Blood Pressure, Overweight, Obesity
Interventions
Vitamin D ergocalciferol, Probenecid, Allopurinol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Jul 24, 2026, 9:14 AM EDT
Terminated Phase 1 Interventional

Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension

NCT02245230
View directory record Official record
Conditions
Hypertension, Hypertension, Essential
Interventions
Angiotensin (1-7), Trimethaphan, Phenylephrine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Jul 24, 2026, 9:14 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

NCT04971720
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases, Hypertension, Nocturnal Blood Pressure, Natriuretic Peptides, Renin-Angiotensin-Aldosterone System
Interventions
Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet, Valsartan 80 mg Oral Tablet
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 24, 2026, 9:14 AM EDT
Not yet recruiting Not applicable Interventional

RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

NCT07605390
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Epic-Based Clinician Notification, Usual Care
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 24, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure

NCT00853658
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Enalapril, Aliskiren
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
58
States / cities
Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2016 · Synced Jul 24, 2026, 9:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Methohexital v Propofol as General Anesthetic in Patients on ACEIs or ARBs

NCT02624050
View directory record Official record
Conditions
Hypotension, Anesthesia
Interventions
Methohexital, Propofol
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jul 24, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

NCT03066804
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
sacubitril/valsartan, Enalapril, Valsartan, Placebo to match sacubitril/valsartan, Placebo to match enalapril, Placebo to match valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
2,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Andalusia, Alabama • Mobile, Alabama • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Jul 24, 2026, 9:14 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

NCT01432106
View directory record Official record
Conditions
Hypertension, Metabolic Syndrome
Interventions
Aliskerin/Valsartan and Rampiril
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 17, 2013 · Synced Jul 24, 2026, 9:14 AM EDT
Terminated Early Phase 1 Interventional

Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure

NCT02591173
View directory record Official record
Conditions
Autonomic Nervous System Disorders, Pure Autonomic Failure, Shy-Drager Syndrome, Orthostatic Hypotension, Dysautonomic
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Jul 24, 2026, 9:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

NCT04752293
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation, Left Ventricular Diastolic Dysfunction, Kidney Diseases, Kidney Injury, Kidney Dysfunction, Sodium Urine High, Blood Pressure Disorders, Uric Acid Retention, Angiotensin Hypertension, Autonomic Dysfunction, Autonomic Imbalance, Pediatric Kidney Disease, Pediatric Obesity, Proteinuria, Albuminuria
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Years to 18 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 24, 2026, 9:14 AM EDT
Recruiting No phase listed Observational

Evaluation of Plasma Renin Concentrations in Cardiac Surgery

NCT06895213
View directory record Official record
Conditions
Cardiac Surgery With Cardiopulmonary Bypass
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 24, 2026, 9:14 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Novel Experimental COVID-19 Therapies Affecting Host Response

NCT04924660
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
Interventions
TXA127, TRV027, Placebo, Fostamatinib
Drug
Lead sponsor
Sean Collins
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
51
States / cities
Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Jul 24, 2026, 9:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV

NCT01407237
View directory record Official record
Conditions
HIV-infection
Interventions
Angiotensin II Infusion
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Jul 24, 2026, 9:14 AM EDT
Completed Phase 4 Interventional Results available

Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)

NCT01328769
View directory record Official record
Conditions
Hypertension
Interventions
Febuxostat, Placebo
Drug
Lead sponsor
Paul N. Hopkins
Other
Eligibility
18 Years to 60 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 16, 2015 · Synced Jul 24, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

NCT03888066
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer, Placebos
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
133
States / cities
Alexander City, Alabama • Huntsville, Alabama • Phoenix, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Jul 24, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

HALT Progression of Polycystic Kidney Disease Study A

NCT00283686
View directory record Official record
Conditions
Kidney, Polycystic
Interventions
Lisinopril, Telmisartan, Placebo, Standard Blood Pressure Control, Low Blood Pressure Control
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years to 64 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Jul 24, 2026, 9:14 AM EDT
Completed Phase 4 Interventional Results available

Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism

NCT02034435
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Low Salt diet plus Placebo tablet, Low Sodium diet plus Salt tablet, Epleronone, Amlodipine
Other · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jul 24, 2026, 9:14 AM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

NCT01356849
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetic Nephropathy
Interventions
Atrasentan, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
59
States / cities
Pell City, Alabama • Tempe, Arizona • Azusa, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Jul 24, 2026, 9:14 AM EDT